No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
July 2018
Sutro Biopharma raises a $85,400,000 series E round from Lilly Ventures, Samsara BioCapital, Alta, Skyline Ventures, Amgen Ventures, SV Health Investors, Celgene and Surveyor Capital.
December 11, 2013
Sutro Biopharma raises a $26,000,000 series D round from Amgen, Skyline Ventures, Alta Partners and Celgene.
November 17, 2010
Sutro Biopharma raises a $36,500,000 series C round from Amgen, Skyline Ventures, Alta Partners and Lilly Ventures.
December 10, 2007
Sutro Biopharma raises a $21,000,000 series B round from Alta Partners.
January 1, 2006
Sutro Biopharma raises a $1,000,000 series A round.
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
85,400,000
July 2018
26,000,000
December 11, 2013
36,500,000
November 17, 2010
People
Name
Role
LinkedIn
Alison Polite
Employee
Avi Hermosa Petel
Employee
Gabriel Jagoe-Seidl
Employee
Jay Shukert
Employee
Jennifer Batara
Employee
Kenneth Larsen
Employee
Lillian Tong
Employee
Marcie Arjona
Employee
Marianna Pristupa
Employee
Patricia Sinatra
Investor
Peter Priel
Employee
Philip Tagari
Investor
Sutanto Widjaja
Founder
Tessi Kanavarioti
Employee
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Sutro Biopharma
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
Sutro Biopharma
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
Amirah Al Idrus
December 4, 2020
FierceBiotech
Sutro Biopharma's lead antibody-drug conjugate beat back ovarian cancer in a small phase 1 study, shrinking tumors in 13% of patients who had tried a median of six other treatments including chemotherapy, Genentech's Avastin, PARP inhibitors and checkpoint inhibitors.
Sutro Biopharma
December 3, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
December 1, 2020
BioSpace
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
BioSpace
November 18, 2020
BioSpace
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced today the appointment of two executives to the Company's leadership team.
Sutro Biopharma
November 18, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
BioSpace
May 21, 2020
BioSpace
Sutro Biopharma, Inc. announced the appointment of Craig Berman, M.D., as Vice President of Clinical Development and the promotion of Regina Cheng to Vice President of Finance and Controller.
BioSpace
May 21, 2020
BioSpace
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced the appointments of Carlos Paya, M.D., Ph.D., as Chair of the Scientific Advisory Board and Lainie Martin, M.D., as a member of the Clinical Advisory Board.
National Hispanic Health Foundation
Invalid Date
www.prnewswire.com:443
LOS ÁNGELES, 11 de diciembre de 2018 /PRNewswire-HISPANIC PR WIRE/ -- El jueves 13 de diciembre, la Fundación Nacional para la Salud Hispana (National Hispanic ...
National Hispanic Health Foundation
Invalid Date
www.prnewswire.com:443
LOS ANGELES, Dec. 11, 2018 /PRNewswire/ -- On Thursday, December 13th, the National Hispanic Health Foundation will honor outstanding health professional...
Is a
Company attributes
Industry
Location
B2X
Founder
Total funding amount (USD)
170,205,000
Latest funding round date
July 2018
